Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1997-1-16
|
| pubmed:abstractText |
The treatment of individuals at risk of Alzheimer disease is feasible in well-designed, placebo-controlled, double-blind studies. The favored design would be life survival for cognitive impairment, alterations in instrumental ADL, and selected biological variables.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0893-0341
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
19-21
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1996
|
| pubmed:articleTitle |
Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease.
|
| pubmed:affiliation |
McGill Centre for Studies in Aging, Hôpital Sacré-Coeur de Montréal, Montreal, Canada.
|
| pubmed:publicationType |
Journal Article
|